Key facts
- Notable investors include Zinc.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Respiro Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Respiro Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Respiro Diagnostics
Developer of a non-invasive breath test technology designed for early detection of lung cancer. The company offers a proprietary sample collection and molecular analysis process that delivers clinically actionable results to physicians without relying on traditional imaging or invasive procedures, enabling clinicians to make informed treatment decisions and patients to access timely treatment.
- Sector
- Healthcare
- HQ
- Leeds, United Kingdom
- Founded
- 2025
- Employees
- 2
- Website
- respirodiagnostics.com/
- Ownership
- Privately Held (backing)
Respiro Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Respiro Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Respiro Diagnostics in its N-PORT filings yet. We sweep new filings monthly.